- Söderlund, P. et al. 10 year results of a new low-monomer cement. Acta Ortopaedica. 83 (6):604-8, 2012.
- Pitto, RP, et al. Cemex Genta bone cement in total hip arthroplasty. Clinical outcome and radiostereoanalysis of 25 hips with 2-year follow-up. South Auckland Clinical School, 2003.
- Pitto, RP. Cemex System Genta bone cement in total hip arthroplasty: clinical outcome and radiostereoanalysis. A 5-year follow-up. South Auckland Clinical School, 2007.
- Dahl, J., et al. Less wear with aluminium-oxide heads than cobalt- chrome heads with ultra-high molecular weight cemented polyethylene cups: a ten-year follow-up with radiostereometry. International Orthopaedics. 36 (3):485-90, 2012.
- Nivbrant, B., et al. Bone cement with reduced proportion of monomer in total hip arthroplasty: pre-clinical evaluation and randomized study of 47 cases with 5 years’ follow-up. Acta Orthopaedica Scandinavica. 72 (6):572-84, 2001.
- Norwegian Arthroplasty Register (NAR). Survival rate – Hip arthroplasy. Report 2017.
- Norwegian Arthroplasty Register (NAR). Survival rate – Knee arthroplasy. Report 2017.
- Swedish Hip Arthroplasty Register (SHAR ). Survival rate – Hip arthroplasy. Report 2018.
- Kühn, K-D. Bone Cements, Up-to-Date Comparison of Physical and Chemical Properties of Commercial Materials. pp. 254-58. Springer Verlag: Berlin, 2000.
- Data on file at TECRES S .P .A. Conflow and Conflow G Bone Cement Characterization and AB release.*
- Malchau, H., et al. Prognosis of Total Hip Replacement. The National Hip Arthroplasty Register. 9-11, 1996.
- Malchau, H., et al. The Swedish Total Hip Replacement Register. Journal of Bone and Joint Surgery. 84A: 2-20, 2002.
- Swedish Hip Arthroplasty Register. Annual Report 1998.
*Laboratory testing is not necessarily indicative of clinical performance
#Data was collected on equivalent devices of the legal manufacturer
Refobacin® is a trademark licensed from Merck KGaA.